Login / Signup

Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial.

Wen ZhangChunxia DuYongkun SunLin YangChengxu CuiZhichao JiangChengfeng WangJinwang WangAiping Zhou
Published in: Cancer chemotherapy and pharmacology (2018)
Nab-paclitaxel and S-1 regimen has presented encouraging ORR, OS, and manageable toxicities as first-line therapy for advanced pancreatic cancer.
Keyphrases
  • advanced non small cell lung cancer
  • open label
  • randomized controlled trial
  • epidermal growth factor receptor
  • study protocol